To determine whether the humanised α-LGR5 antibody could also be used therapeutically, we treated NALM6 tumour-bearing mice with two doses of 5 mg/kg α-LGR5v4-ADC or 5 mg/kg of the non-binding control α-LGR5v6-ADC on days 6 and 8 post tumour implantation (PI). This evidence concerns the gene LGR5 and neoplasm.